Clinical Trials Logo

Multi-Antiviral Resistance clinical trials

View clinical trials related to Multi-Antiviral Resistance.

Filter by:
  • None
  • Page 1

NCT ID: NCT05388474 Recruiting - HIV Infections Clinical Trials

A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without Ibalizumab

PROMISE-US
Start date: March 22, 2022
Phase:
Study type: Observational

The virological efficacy of ibalizumab has been clearly demonstrated in multiple clinical trials. This study will expand ibalizumab's clinical data set and allow a better understanding of the virologic response durability on ARV regimens with or without ibalizumab in a heterogeneous real-world patient population. Additional data on the efficacy and safety of ibalizumab and its impact on patient reported outcomes will be captured until study end. Primary Objective: To evaluate the long-term efficacy, safety, and durability of ibalizumab in combination with other ARVs by comparing the virologic, immunologic and clinical outcomes of patients receiving ibalizumab treatment versus patients not receiving ibalizumab. Secondary Objective: To assess the efficacy of ibalizumab in combination with other antiretrovirals by comparing the virologic, immunologic, clinical and patient reported outcomes of patients before and after they receive ibalizumab treatment. To assess the long-term safety and tolerability of ibalizumab. Other Objectives: To assess risk factors/predictors of virologic and immunologic response. To assess efficacy and safety in special populations that enroll.

NCT ID: NCT04098315 Recruiting - HIV-1-infection Clinical Trials

Italian Registry of HIV-1 Infected Patients With Drug-RESistant Virus to Reverse Transcriptase Inhibitors, InteGrasE and Viral Protease.

PRESTIGIO
Start date: December 14, 2017
Phase:
Study type: Observational [Patient Registry]

The PRESTIGIO Registry is an Observational, prospective, multicentre study that includes patients, regularly followed by Italian Infectious Disease Centres, with HIV-1 infection and documented resistance to the 4 classes of antiretroviral drugs: nucleoside reverse transcriptase inhibitors (NRTI), non-nucleoside reverse transcriptase inhibitors (NNRTI), protease inhibitors (PI), and integrase inhibitors (INSTI). Main objective of this register is to evaluate in the study population: - the long-term effectiveness of different antiretroviral regimes; - evolution of the genotype and phenotypic susceptibility of antiretroviral drugs used in patients with virological failure; - mortality; - incidence of opportunistic AIDS-related infections and chronic conditions (comorbidity); - determinants of clinical outcomes including virological/immunological/inflammatory markers. - antiretroviral therapy (ART) compliance and health assessments; - drug-economy indications related to the clinical management of this complex sub-population.